Reductions in mortality shown using blood pressure-lowering treatment in elderly
Lowering the blood pressure of elderly patients could cut their total mortality by a fifth and their rate of cardiovascular events by a third, according to a new study presented today at the American College of … via Huliq.com
New Data Showed Actos (pioglitazone HCl) Prevented Progression of…
“We are pleased with the results of the PERISCOPE, which further expands our cardiovascular data with ACTOS”
New data from a clinical trial using intravascular ultrasound technology found that in patients living with type 2 diabetes, ACTOS reduced the atherosclerotic burden in the coronary arteries compared to … via Med Ad News
Diabetes drug also reduces risk of heart attacks, say researchers
Comments Actos prevents the build-up of plaque in the arteries thus lowering the risk of heart attacks A new glucose-lowering drug used in diabetics also cuts the build-up of plaque in the arteries, say … via Daily Mail
Spanish Appellate Court Rules in Pfizer’s Favor, Upholds Lipitor Patent
NEW YORK–(BUSINESS WIRE)–Mar 31, 2008 - Pfizer Inc said today
that the Court of Appeal of Barcelona has upheld the company’s
enantiomer patent covering the calcium salt of atorvastatin, the
active ingredient in Lipitor, reversing the lower court…
Study indicates diabetes medication may help slow plaque build-up in coronary arteries
A comparison of two types of medications to treat type 2 diabetes finds that pioglitazone is more effective at lowering the rate of progression of plaque build-up in the coronary arteries than glimepiride, … via EurekAlert!
Naglazyme Approved by Japanese Ministry of Health
NOVATO, Calif., March 31, 2008 /PRNewswire-FirstCall/ –
BioMarin Pharmaceutical Inc. announced today that AnGes MG, Inc.
(AnGes), BioMarin’s marketing and distribution partner in Japan,
has received approval for its Marketing Application…
Verispan Reports: Physicians Prefer Merck’s ePromotion Activities
YARDLEY, Pa.–(BUSINESS WIRE)–Mar 31, 2008 - According to
Verispan’s 2007 ePromotion Annual Study, physicians were most
likely to report that Merck had the best ePromotion activities. Of
the approximately 1,000 physicians who participated, Merck…
Teva to Acquire Bentley Pharmaceuticals
JERUSALEM & EXETER, N.H.–(BUSINESS WIRE)–March 31, 2008 -
Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and Bentley
Pharmaceuticals, Inc. (NYSE: BNT) announced today that they have
entered into a definitive agreement under which Teva will…
Phase II results for CDP791 in non-small cell lung cancer support further clinical development
UCB today announces first results of its phase II exploratory study of CDP791, a specific VEGFR-2/KDR inhibitor, in combination with carboplatin and paclitaxel chemotherapy in first line non-small cell lung … via Earth Times
Comparison of anticoagulants for angioplasty show similar outcomes
In a comparison of anticoagulants and stents for use with angioplasty following a heart attack, the anticoagulants abciximab and tirofiban had similar outcomes for some cardiac measures within 90 minutes after … via EurekAlert!
keep looking »